RxDoctor Payments Data

Keyna Martinez, MD

Family Medicine · Bremen, INNPI 1013941699

Payments from drug & device makers

$3,661in general payments, 2019–2025

Across 195 payments — averaging $18.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$585
  • AstraZeneca$515
  • Pfizer$398
  • Novo Nordisk$327
  • Lilly USA, LLC$248
  • Bayer$213
  • plus $1K from 29 others

What the payments were for

  • Food & beverage$3,64199%
  • Education$201%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,661 in reported general payments places this provider in the 80th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$70,921
Medicare patients
216
Services billed
853

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban95$95,722
JardianceEmpagliflozin56$88,490
OzempicSemaglutide51$83,223
FarxigaDapagliflozin Propanediol56$64,543
TrulicityDulaglutide31$53,230
MounjaroTirzepatide45$48,935
Trelegy ElliptaFluticasone/Umeclidin/Vilanter35$41,914
Spiriva RespimatTiotropium Bromide21$20,951
Tresiba Flextouch U-200Insulin Degludec18$18,175
Xtampza ErOxycodone Myristate12$11,665
SymbicortBudesonide/Formoterol Fumarate19$8,819
Emgality PenGalcanezumab-Gnlm11$7,817
Lantus SolostarInsulin Glargine,hum.Rec.Anlog31$7,365
Pregabalin155$5,766
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl23$4,522

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Spiriva Respimat$128$109,44277 claims
Lilly USA, LLCTrulicity, Mounjaro$248$102,16576 claims
PfizerEliquis$398$95,72295 claims
Novo NordiskOzempic$327$83,22351 claims
AstraZenecaFarxiga, Symbicort$515$73,36375 claims
GSKTrelegy Ellipta$33$41,91435 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Bremen

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →